TABLE 3

Effect on islet allograft survival of adoptive transfer of in vivo alloMHC peptide–primed syngeneic T-cells

GroupALS immunosuppression (0.5 ml on day −7)Injection of in vivo P5-primed T-cells (route)Islet donorSurvival time (days)MST ± SD (days)
I2 × 107 T-cells (i.v.)WF4, 4, 4, 5, 5, 5, 5, 54.6 ± 0.5
II2 × 107 T-cells (i.v.)BN7, 8, 8, 87.8 ± 0.5
III0.5 ml2 × 107 T-cells (i.v.)WF>200 (6 animals)>200
IV0.5 ml2 × 107 T-cells (i.v.)BN9, 11, 12, 1411.5 ± 2.1
V2 × 107 T-cells (i.t.)WF14, 15, 17, 2116.8 ± 3.1
VI2 × 107 T-cells (i.t.)BN7, 8, 8, 8, 98.0 ± 0.6
VII0.5 ml2 × 107 T-cells (i.t.)WF35, 38, >200 (6 animals)>200
VIII0.5 ml2 × 107 T-cells (i.t.)BN10, 11, 11, 1211.0 ± 0.8
  • ACI recipients were pretreated with intravenous (i.v.) or intrathymic (i.t.) injection of in vivo P5-primed syngeneic T-cells obtained from the spleen of ACI rats inoculated 7 days earlier with 2 × 106 P5-pulsed DC combined with or without 0.5 ml ALS intraperitoneal immunosuppression. Each recipient was transplanted with intraportal injection of 1,200–1,500 islets obtained from WF (donor) or BN (third party).